Azenta (AZTA) Q2 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 Greetings and welcome to the Azenta Q2 twenty twenty five Financial Results. During the presentation, all participants will be in a listen only mode. Afterwards, we will conduct a question and answer session. As a reminder, this conference is being recorded Wednesday, 05/07/2025. I will now turn the conference over to Yvonne Perron, Vice President, FP and A and Investor Relations. Speaker1 Thank you, operator, and good morning to everyone ...

© 2025 Azenta, Inc. • All rights reserved 1 Conference Call Fiscal Second Quarter 2025 Financial Results May 7, 2025 1 Safe Harbor Statement "Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, from those projected. ...

Core Insights - The company reported a total revenue of $143 million for the quarter ended March 31, 2025, reflecting a 5% increase year-over-year, driven by growth in Sample Management Solutions and Multiomics [2][7] - The diluted EPS from continuing operations was $(0.40), compared to $(0.29) in the same quarter of the previous year, indicating a significant loss [2][24] - The company has a strong cash position with total cash, cash equivalents, and marketable securities amounting to $540 million as of March 31, 2025 [14] Financial Performance - Revenue from continuing operations was $143 million, down 3% from the previous quarter but up 5% year-over-year [2][7] - Organic revenue growth was 6% year-over-year, with Sample Management Solutions revenue at $80 million, up 8% year-over-year [2][7] - Adjusted EBITDA for continuing operations was $14 million, with an adjusted EBITDA margin of 10.0%, an improvement of 400 basis points year-over-year [2][7] Management Commentary - The CEO highlighted the company's strong performance amidst a challenging macroeconomic environment, emphasizing the resilience of the portfolio and the commitment of the teams [3] - The management expressed confidence in the company's positioning and disciplined operations while navigating uncertainties [3] Cash Flow and Guidance - Operating cash flow for the quarter was $14 million, with capital expenditures of $7 million, resulting in free cash flow of $7 million [14] - The company reiterated its revenue guidance for fiscal year 2025, expecting total organic revenue growth in the range of 3% to 5% compared to fiscal 2024 [14]

BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay ...

BURLINGTON, Mass., March 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2024.The report offers a comprehensive look at the Company's ESG approach and showcases accomplishments in three main pillars: Environmental ...

BURLINGTON, Mass., March 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) announced that Lawrence Y. Lin, Executive Vice President and Chief Financial Officer, will participate in the Virtual KeyBanc Capital Markets Healthcare Forum on Wednesday, March 19, 2025, which includes a presentation beginning at 10:30 am ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.About Az ...

Investors in Azenta, Inc. (AZTA) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec. 19, 2025 $22.5 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04 ...

Conference Call 1 Fiscal First Quarter 2025 Financial Results Februar y 5, 2025 1 © 2025 Azenta, Inc. • All rights reserved Safe Harbor Statement This presentation contains certain non-GAAP measures which are provided to assist in an understanding of the Azenta business and its operational performance. These measures should always be considered in conjunction with the appropriate GAAP measure. Reconciliations of all non-GAAP amounts to the relevant "Safe Harbor" Statement under the U.S. Private Securities L ...

Financial Data and Key Metrics Changes - First quarter revenue was $148 million, representing a 4% year-over-year growth on both reported and organic basis [44][45] - Non-GAAP EPS for the quarter was $0.08, with adjusted EBITDA margin at 9%, reflecting a 400 basis points expansion year-over-year [45][46] - Free cash flow was $22 million for the quarter, with $530 million in cash, cash equivalents, and marketable securities at quarter-end [46][54] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $81 million, up 3% year-over-year, driven by growth in Sample Repository Solutions and Core Products [49] - Multiomics segment delivered revenue of $66 million, with a growth of 6% year-over-year, supported by strong performance in Next Generation Sequencing (NGS) and Gene Synthesis [51][52] Market Data and Key Metrics Changes - In China, organic revenue growth was 7%, outperforming the market despite macro challenges [52] - NGS grew 11% year-over-year, indicating stabilization in pricing and volume growth [51][122] Company Strategy and Development Direction - The company is focused on portfolio optimization, operational excellence, and value-enhancing capital allocation [20][22] - The Value Creation Committee has been established to oversee strategic initiatives and capital allocation decisions [35][112] - The company aims to maintain a disciplined approach to capital allocation, prioritizing growth initiatives and operational improvements over share buybacks [111][112] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about gradual market recovery, reiterating full-year 2025 guidance of organic revenue growth between 3% to 5% and adjusted EBITDA margin expansion of 300 basis points [19][55] - The management highlighted the importance of continuous improvement and simplification in operations to drive long-term value creation [22][24] Other Important Information - The results of B Medical Systems are now treated as discontinued operations, and the sale process is underway [4][17] - The company is implementing a new business system and operating model to enhance operational efficiency and performance [23][24] Q&A Session Summary Question: Size and timing of the U.K. Biocentre BioArc opportunity - Management confirmed that the BioArc Ultra project was included in guidance and is expected to be operational early in 2026 [60][62] Question: Impact of Illumina being added to the unreliable entity list in China - Management indicated low risk to NGS business in China, as most operations are partnered with BGI, allowing for flexibility in platform usage [64][66] Question: Guidance for Multiomics and potential deceleration - Management acknowledged that guidance reflects a cautious outlook, with NGS experiencing strong growth but potential challenges in Sanger Sequencing [70][72] Question: Status of B Medical sale process - Management stated that the sale process is still in initial stages, with a focus on maximizing value [82][83] Question: Exposure to tariffs in China, Mexico, and Canada - Management assessed that the impact of tariffs is immaterial, with minimal risk from operations in Mexico and Canada [89][90] Question: Guidance for Sample Management Solutions - Management noted that timing issues affected SMS performance, but a robust pipeline and backlog are in place for future growth [92][93] Question: Gross margin sustainability and operating margin ramp - Management expressed confidence in gross margin trajectory, with expectations for continued improvement [98] Question: Academic and government exposure and NIH impact - Management confirmed that recent delays in government-funded projects are expected to resume once funding decisions are made [102][103] Question: Cell and gene therapy market performance - Management reported strong progress in the auto cryo business related to cell and gene therapy, with significant growth observed [106] Question: Share buyback program and M&A strategy - Management clarified that share buybacks are a lower priority compared to growth initiatives and M&A opportunities, with a focus on demonstrating operational credibility first [111][112][114]